Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years, according to the European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology (ESC) and the American Society of Echocardiography (ASE).

16 Jul 2013

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced positive results from their second placebo-controlled Phase 1 study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor, and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.

12 Jul 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Saltwater-treatment for cystic fibrosis: an interview with Matthew Allen, Program Director at Cambridge Consultants

A group of Australian researchers, back in 2006, noted that there was a link between the severity of cystic fibrosis between sufferers who surfed, and sufferers who did not surf – and obviously Australia is a good place to spot that.

4 Jul 2013

Research unravels a novel means of communication that allows bacteria to resist antibiotic treatment

New research from Western University unravels a novel means of communication that allows bacteria such as Burkholderia cenocepacia (B. cenocepacia) to resist antibiotic treatment. B. cenocepacia is an environmental bacterium that causes devastating infections in patients with cystic fibrosis (CF) or with compromised immune systems.

4 Jul 2013

Scientists uncover easy strategies to prevent harmful side-effects of antibiotics responses

A team of scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University has discovered why long-term treatment with many common antibiotics can cause harmful side effects-and they have uncovered two easy strategies that could help prevent these dangerous responses.

4 Jul 2013

Scientists track down origins of fibrosis-promoting cells that scar and destroy organs

Scientists have tracked down and quantified the diverse origins of cells that drive fibrosis, the incurable, runaway wound-healing that scars and ultimately destroys organs such as the lungs, liver and kidneys.

2 Jul 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

A paradigm shift for treatment of muscular dystrophy

Researchers at Boston University College of Health & Rehabilitation Sciences: Sargent College have identified a combinatorial therapeutic approach that has proven effective in treating muscular dystrophy in a mouse model.

26 Jun 2013

Study reports catheter ablation is more effective in preventing AFrecurrence

Using catheter ablation to create complete linear lesions around pulmonary veins, proved more effective than the creation of incomplete lesions in preventing recurrence of atrial fibrillation (AF), reports the GAP-AF study.

25 Jun 2013

HIV-derived antibacterial compounds could be potential treatments for drug-resistant bacterial infections

A team of researchers at the University of Pittsburgh has developed antibacterial compounds, derived from the outer coating of HIV, that could be potential treatments for drug-resistant bacterial infections and appear to avoid generating resistance. These new agents are quite small, making them inexpensive and easy to manufacture.

20 Jun 2013

Staph-killing compound may be effective against osteomyelitis

Osteomyelitis - a debilitating bone infection most frequently caused by Staphylococcus aureus ("staph") bacteria - is particularly challenging to treat.

20 Jun 2013

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

InterMune, Inc. today announced that the Board of the Italian Drug Agency has approved the pricing and reimbursement conditions for Esbriet (pirfenidone), and that the agreement has been published in the Official Gazette, the official journal of the government of Italy.

15 Jun 2013

Viewpoints: 'Tyranny' over insurers; Obama's promises; Rep. Franks's abortion claim

Many of us wish that Obamacare were a simpler system, one that directly provided health insurance. Political reality, unfortunately, ensured that many people will receive coverage from private insurers, selling policies - often with subsidies - on the "exchanges". And naturally enough, the Obama administration is teaming up with the insurers and other parts of the health industry to help inform Americans of the benefits to which they will be legally entitled, starting Jan. 1 (Paul Krugman, 6/12).

14 Jun 2013

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4 billion) Series C financing.

13 Jun 2013

Johns Hopkins researchers develop experimental vaccine for TB meningitis

A team of Johns Hopkins researchers working with animals has developed a vaccine that prevents the virulent TB bacterium from invading the brain and causing the highly lethal condition TB meningitis, a disease that disproportionately occurs in TB-infected children and in adults with compromised immune system.

12 Jun 2013

Fibrosis News and Research

Further Reading

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years

RXi Pharmaceuticals reports positive results from second Phase 1 study with RXI‑109

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Saltwater-treatment for cystic fibrosis: an interview with Matthew Allen, Program Director at Cambridge Consultants

Research unravels a novel means of communication that allows bacteria to resist antibiotic treatment

Scientists uncover easy strategies to prevent harmful side-effects of antibiotics responses

Scientists track down origins of fibrosis-promoting cells that scar and destroy organs

Eisai submits BELVIQ NDS with Health Canada

A paradigm shift for treatment of muscular dystrophy

Study reports catheter ablation is more effective in preventing AFrecurrence

HIV-derived antibacterial compounds could be potential treatments for drug-resistant bacterial infections

Staph-killing compound may be effective against osteomyelitis

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

Viewpoints: 'Tyranny' over insurers; Obama's promises; Rep. Franks's abortion claim

PRISM Pharma announces closing of $15 million Series C financing

Johns Hopkins researchers develop experimental vaccine for TB meningitis

Study shows iron-uptake receptor plays a role in HCV infection

Children's Hospitals and Clinics of Minnesota honored as 2013-2014 Best Children's Hospital

Debate over a dying child and a lack of transplant organs

MRI scans of children who have undergone chemotherapy can detect early changes in their hearts

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News